The role of blood pressure lowering before and after stroke

Current Opinion in Neurology

Volumn 16, Issue 1, 2003, Pages 81-86

  Donnan, Geoffrey A ^a   Davis, Stephen M ^b   Thrift, Amanda ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Blood pressure; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCERYL TRINITRATE; INDAPAMIDE; LOSARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; WARFARIN;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DRUG EFFECT; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; META ANALYSIS; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; STROKE; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; CEREBRAL INFARCTION; HUMANS; HYPERTENSION; PERINDOPRIL; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; TREATMENT OUTCOME;

EID: 0037321129     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200302000-00011     Document Type: Review

References (54)

1. Bonita R. Epidemiology of stroke. Lancet 1992; 339:342-344.
2. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50:272-298.
3. MacMahon S, Rodgers A. Blood pressure, antihypertensive treatment and stroke risk. J Hypertens Suppl 1994; 12:S5-S14.
4. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356:1955-1964.
5. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335:827-838.
6. Bonita R, Beaglehole R. Does treatment of hypertension explain the decline in mortality from stroke? Br Med J (Clin Res Ed) 1986; 292:191-192.
7. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765-774.
8. Rodgers A, MacMahon S, Gamble G, et al. Blood pressure and risk of stroke in patients with cerebrovascular disease. The United Kingdom Transient Ischaemic Attack Collaborative Group. Br Med J 1996; 313:147.
9. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet 1998; 352:1801-1807.
10. MacMahon S, Rodgers A. Primary and secondary prevention of stroke. Clin Exp Hypertens 1996; 18:537-546.
11. Chalmers J, MacMahon S, Anderson C, et al. Clinician's manual on blood pressure and stroke prevention. 2nd ed. London: Science Press; 2000.
12. Chalmers J, Chapman N. Challenges for the prevention of primary and secondary stroke: the importance of lowering blood pressure and total cardiovascular risk. Blood Press 2001; 10:344-351.
13. Blood pressure in Acute Stroke Collaboration. Interventions for deliberately altering blood pressure in acute stroke. Blood pressure in Acute Stroke Collaboration (BASC). Cochrane Database Syst Rev 2000; (2):CD000039.
14. Thrift AG, Donnan GA, McNeil JJ. Epidemiology of intracerebral hemorrhage. Epidemiol Rev 1995; 17:361-381.
15. You R, McNeil JJ, O'Malley HM, et al. Risk factors for lacunar infarction syndromes [see comments]. Neurology 1995; 45:1483-1487.
16. Donnan G, You R, Thrift A, et al. Hypertension as a risk factor for stroke subtypes. Hypertens Res 1994; 17:S51-S54.
17. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
18. Lindholm L, Ibsen H, Dahlor B, et al. The LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction to hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:1004-1010. •• This describes the LIFE study, the first head to head study between an A2 antagonist and a beta blocker. Significant protection against fatal and non-fatal stroke was shown for losartan in spite of similar blood pressure reductions seen in the atenelol group.
19. Hansson L, Lithell H, Skoog I, et al. Study on COgnition and Prognosis in the Elderly (SCOPE): baseline characteristics. Blood Press 2000; 9:146-151.
20. Hansson L, Lithell H, Skoog I, et al. Study on COgnition and Prognosis in the Elderly (SCOPE). Blood Press 1999; 8:177-183.
21. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90:2056-2069.
22. Pepine CJ. Improved endothelial function with angiotensin-converting enzyme inhibitors. Am J Cardiol 1997; 79:29-32.
23. Inada Y, Wada T, Ojima M, et al. Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 1997; 19:1079-1099.
24. Ravati A, Junker V, Kouklei M, et al. Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and rats. Eur J Pharmacol 1999; 373:21-33.
25. Culman J, Blume A, Gohlke P, Unger T. The renin-angiotensin system in the brain: possible therapeutic implications for AT(1)-receptor blockers. J Hum Hypertens 2002; 16 (suppl 3):S64-S70.
26. Bath P, Boysen G, Donnan G, et al. Hypertension in acute stroke: what to do? Stroke 2001; 32:1697-1698.
27. Broderick J, Brott T, Barsan W, et al. Blood pressure during the first minutes of focal cerebral ischemia. Ann Emerg Med 1993; 22:1436-1443.
28. Britton M, Carlsson A, de Faire U. Blood pressure course in patients with acute stroke and matched controls. Stroke 1986; 17:861-864.
29. Irie K, Yamaguchi T, Minematsu K, Omae T. The J-curve phenomenon in stroke recurrence. Stroke 1993; 24:1844-1849.
30. Dandapani BK, Suzuki S, Kelley RE, et al. Relation between blood pressure and outcome in intracerebral hemorrhage. Stroke 1995; 26:21-24.
31. Ahmed N, Wahlgren G. High initial blood pressure after acute stroke is associated with poor functional outcome. J Intern Med 2001; 249:467-473.
32. Leonardi-Bee J, Bath PM, Phillips SJ, Sandercock PA. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 2002; 33:1315-1320.
33. Ahmed N, Nasman P, Wahlgren NG. Effect of intravenous nimodipine on blood pressure and outcome after acute stroke. Stroke 2000; 31:1250-1255.
34. Olsen TS, Bruhn P, Oberg RG. Cortical hypoperfusion as a possible cause of 'subcortical aphasia'. Brain 1986; 109 (Pt 3):393-410.
35. Touzani O, Roussel S, MacKenzie ET. The ischaemic penumbra. Curr Opin Neurol 2001; 14:83-88.
36. Bladin CF, Chambers BR. Frequency and pathogenesis of hemodynamic stroke. Stroke 1994; 25:2179-2182.
37. Dyker AG, Grosset DG, Lees K. Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Stroke 1997; 28:580-583.
38. Lisk DR, Grotta JC, Lamki LM, et al. Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Arch Neurol 1993; 50:855-862.
39. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333:1581-1587.
40. Bath PM, Weaver C, Iddenden R, Bath FJ. A trial of blood pressure reduction in acute stroke. Age Ageing 2000; 29:554-555.
41. Bath P, Bath F, Rashid P, Weaver C. Acute ischaemic stroke. Large trial of effect of reducing blood pressure in acute stroke is being set up [letter]. Br Med J 2000; 321:300.
42. Bath PM. Efficacy of nitric oxide in stroke (ENOS) Trial [abstract]. Stroke 2001; 32:2450-2451.
43. Schrader J, Rothemeyer M, Luders S, Kollmann K. Hypertension and stroke rationale behind the ACCESS trial. Acute Candesartan Cilexetil Evaluation in Stroke Survivors. Basic Res Cardiol 1998; 93 (suppl 2):69-78.
44. Schrader J, Luders S, Kulschewski A, et al. ACCESS-Study: Acute candesartan dilexetil evaluation in stroke survivors [abstract]. Am J Hypertens 2002; 15:17A.
45. Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978; 299:53-59.
46. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143:1-13.
47. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348:1329-1339.
48. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991; 325:445-453.
49. European Carotid Surgery Trialists' Collaborative Group. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. Lancet 1991; 337:1235-1243.
50. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342:1255-1262.
51. Neal B, MacMahon S. PROGRESS (perindopril protection against recurrent stroke study): rationale and design. PROGRESS Management Committee. J Hypertens 1995; 13(12 Pt 2):1869-1873.
52. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-1041. •• This describes the PROGRESS study, the first study to show that reduction of blood pressure in both hypertensive and normotensive people using perindopril based therapy reduces the probability of recurrent stroke, independent of baseline blood pressure level.
53. Gueyffier F, Boissel JP, Boutitie F, et al. Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. Stroke 1997; 28:2557-2562.
54. 1 antagonists.